In the version of this article initially published online, in Figure 3c , the label "unidentified b-type ions" should have been deleted, and in Figure 4 , the symbols over the peptide sequences were misplaced. The errors have been corrected for the print, PDF and HTML versions of this article. In the version of the article initially published, some companies that went public in 2013 were missing from the table of 2013 IPOs (Table 4) . Thirteen companies have been added to the table, including Celyad (formerly Cardio3 Biosciences), Erytech, Immunicum, Innate Immune Therapeutics, Kadimastem, Karyopharm Therapeutics, Kindred, Macrogenics, Oncolys Biopharma, Reprocell, Tetralogic, Veracyte and Xencor; in the figure of global IPOs (Fig. 2) , the number of IPOs in 2013 and the average dollar amount raised have been corrected to reflect the additional companies.
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